参考资料:[1] Servier Presents Transformational Data from Pivotal Phase 3 INDIGO Trial of Vorasidenib in Recurrent or Residual Grade 2 IDH-Mutant Diffuse Glioma. Retrieved June 4, 2023, from https://www.prnewswire.com/news-releases/servier-presents-transformational-data-from-pivotal-phase-3-indigo-trial-of-vorasidenib-in-recurrent-or-residual-grade-2-idh-mutant-diffuse-glioma-301841862.html[2] Servier’s vorasidenib stalls progression of brain cancer by 61% in pivotal PhIII INDIGO study: #ASCO23. Retrieved June 4, 2023, from https://endpts.com/serviers-idh1-2-inhibitor-vorasidenib-stalls-brain-cancer-progression-by-61-in-phiii-study-asco23/